Dose-dense neoadjuvant chemotherapy in breast cancer

2005 
807 Background: Neo-adjuvant chemotherapy has been proven to increase the rate of breast-conservation and represents the standard of care in patients with locally advanced breast cancer. Dose-dense chemotherapy has been shown to improve clinical outcomes in the adjuvant setting in node positive patients. We report here on the efficacy of dose-dense chemotherapy in the neo-adjuvant setting. Methods: We allocated 53 breast cancer patients to receive neo-adjuvant chemotherapy, because of locally advanced disease (T4 or N2+) or in the aim of maximizing breast conservation. All patients received doxorubicin (A) 60 mg/m2, cyclophosphamide (C) 600 mg/m2 and paclitaxel (T) 175 mg/m2, administered as concurrent AC x 4 every 2 weeks followed by T x 4 every 2 weeks. All patients received G-CSF, at an initial dose of 300 mcg, commencing on day 5 for 5 days. Nodal status was evaluated by physical examination, ultrasound, core-needle biopsy or sentinel biopsy prior to chemotherapy. Results: Median age of the patients w...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    1
    Citations
    NaN
    KQI
    []